Your browser doesn't support javascript.
loading
Risk Factors and Outcomes for Multidrug Resistant Pseudomonas aeruginosa Infection in Immunocompromised Patients.
Hernández-Jiménez, Pilar; López-Medrano, Francisco; Fernández-Ruiz, Mario; Silva, J Tiago; Corbella, Laura; San-Juan, Rafael; Lizasoain, Manuel; Díaz-Regañón, Jazmín; Viedma, Esther; Aguado, José María.
Afiliação
  • Hernández-Jiménez P; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), 28041 Madrid, Spain.
  • López-Medrano F; Department of Medicine, School of Medicine, Universidad Complutense, 28040 Madrid, Spain.
  • Fernández-Ruiz M; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), 28041 Madrid, Spain.
  • Silva JT; Department of Medicine, School of Medicine, Universidad Complutense, 28040 Madrid, Spain.
  • Corbella L; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid 28029, Spain.
  • San-Juan R; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), 28041 Madrid, Spain.
  • Lizasoain M; Department of Medicine, School of Medicine, Universidad Complutense, 28040 Madrid, Spain.
  • Díaz-Regañón J; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid 28029, Spain.
  • Viedma E; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), 28041 Madrid, Spain.
  • Aguado JM; Department of Medicine, School of Medicine, Universidad Complutense, 28040 Madrid, Spain.
Antibiotics (Basel) ; 11(11)2022 Oct 23.
Article em En | MEDLINE | ID: mdl-36358114
ABSTRACT

Background:

Pseudomonas aeruginosa (PSA) infection often occurs in immunocompromised patients, which also face an increased risk of multidrug-resistant (MDR) bacteria. A deeper knowledge of the risk factors for MDR-PSA infection in this patient population may help to choose appropriate empirical antibiotic therapy.

Methods:

a single-center case-control (12) retrospective study that included 48 patients with underlying immunosuppression developing MDR-PSA infection (cases) and 96 patients also immunocompromised that were infected with non-MDR-PSA (controls) was conducted. Both groups were matched by site of infection, clinical features and type of immunosuppression. Risk factors for MDR-PSA were assessed by logistic regression. Clinical outcomes were also compared between both groups.

Results:

immunosuppression was due to solid cancer in 63 (43.8%) patients, solid organ transplantation in 39 (27.1%), hematological disease in 35 (24.3%) and other causes in 7 (4.9%). Independent risk factors for MDR-PSA infection were diabetes mellitus (odds ratio [OR] 4.74; 95% confidence interval [CI] 1.63−13.79; p = 0.004), antibiotic therapy in the previous 3 months (OR 5.32; 95% CI 1.93−14.73; p = 0.001), previous MDR-PSA colonization (OR 42.1; 95% CI 4.49−394.8; p = 0.001) and septic shock (OR 3.73; 95% CI 1.36−10.21; p = 0.010). MDR-PSA cases were less likely to receive adequate empirical therapy (14 [29.2%] vs. 69 [71.9%]; p < 0.001). 30-day clinical improvement was less common in MDR-PSA cases (25 [52.1%] vs. 76 [79.2%]; p = 0.001).

Conclusions:

diabetes mellitus, previous MDR-PSA colonization, prior receipt of antibiotics and septic shock acted as risk factors for developing MDR-PSA infections in immunocompromised patients, who have a poorer outcome than those infected with non-MDR-PSA strains.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article